



Newsletter

The 2nd inclusion!

Time for another update on the STEPS-EA trial. At this moment we are making small steps towards the ultimate goal: 110 inclusions. In November we have included our 2nd patient in the trial, who was randomized in the control group. As 20 centers are working their way to their first inclusion at this moment, we expect to report more good news by summer!

Participating centers

The following centers have started the local ethical approval process:

- University Hospital Vall d'Hebron Barcelona (Spain)
- Sant Joan de Déu Barcelona (Spain)
- Clinical Hospital Center Zagreb (Croatia)
- Karolinska Institutet Stockholm (Sweden)
- Bambino Gesù Hospital (Italy)
- Centre Hospitalier Universitaire de Lille (France)

The legal department is reviewing the trial agreement in the following centers:

- Medical University of Vienna (Austria)
- Odense University Hospital (Denmark)
- Hospital Universitario La Paz Madrid (Spain)
- Amsterdam UMC (The Netherlands)
- University Hospital Santaros Klinikos Vilnius (Lithuania).

Lastly, Lund (Sweden), London (United Kingdom), Vienna SMZ Ost (Austria) and Padua (Italy) have expressed their interest in participating in the trial.

Copenhagen (Denmark), Paris (France) and Marseille (France) are waiting for ethical approval received by Odense (Denmark) and Lille (France).

We all know the struggles of an international multicenter trial but only collaboration in projects like this enables us to do high-level research in rare diseases. For any questions or if you are interested to participate, please contact us. We are happy to help you with the logistics in any way possible.

The STEPS-EA trial team steps.ea@erasmusmc.nl

COVID-19 pandemic

Even though the medical staff, ethical committees and legal departments remain very busy keeping up with the COVID-19 pandemic, we see that everybody is working hard on getting this trial up and running.

We appreciate the hard work and expect to make great progress in the coming months!

Road to success



The STEPS-EA trial: intralesional STERoid injections to Prevent refractory Strictures in patients with Esophageal Atresia

→ 1:1 randomization to injection with 10 mg/ml TAC (Kenacort-A 10) prior to balloon dilatation and balloon dilatation without any injection